Replies to post #90020 on DD Support Board and Research Team

[janice shell]

AXON's only been trading for three sessions. It's down from a high of $31.17 to a close today of $22.12. Volume is decreasing.

That certainly suggests that Mr Market has doubts about the drug...

[sidedraft]

What is AXOM?

[DragonBear]

AXOM - Total scam!

Well, let's just say it's not too good to have a failed drug test, and GSK as the article points out, essentially giving the drug's rights away for nearly free.

I especially like this part:

"We think we have a great drug candidate,” Ramaswamy told Forbes. "If this drug is approved we think it's going to make a huge difference for a lot of patients and ultimately there is a huge need and a great team here to do it."

Note to Ramaswamy: Even thought my ex-employer GSK has management which sucks, it's still a large Pharma, with a lot of talented researchers. Certainly they could afford a lot more brain power than a 3 month old podunk biotech start up. GSK also has a well established track record with the FDA. If GSK thought a little fiddling around would enable them to push the drug through FDA approval, they would've gone for it.

But in one trial, when it was given to people along with a widely used drug called Aricept (which is prescribed to treat some of the symptoms of Alzheimer's disease, such as confusion and memory loss), they showed a slower loss over time of some measures of brain functioning and daily capabilities than those who only took the Aricept

That would be interesting data to see. As in what time frame is "slower". The knock on Aricept it slows progression of Alzheimer's, but only in the early stages of the disease. Once the disease progresses to a given stage for an individual Aricept is worthless. It fact it may last only a couple of months in effect, during the early stage of the disease.

For all practical purposes AXON would be starting from scratch. Maybe, they could piggy back on a previous GSK study to bypass Phase I drug trials (safety/dose data). But after that they would have to start with Phase II. Most biotechs or any other drug company doesn't get a boost to its stock until the drug enters Phase III. Yet AXON right out of the gate, having done nothing?

Does seem like a lot of hype over a drug candidate totally unproven. One can only think, there will be a few biotechs out there with far better drug candidates that will struggle for years getting the instant IPO funding AXON did.

[shajandr]

You should look into Hemispherx Biopharma - that's a scam run by an MD that's been pushing a failed "drug" (just bulk RNA; "Ampligen") from the 1960s and been hyping that old, failed crap for 30 years now.

Used to be on AMEX exchange with ticker HEB.

Utter, total tech scam.

Another one along those lines was Hollis-Eden Pharma a scam operated by Richard Hollis - a truly despicable human being - pushing DHEA as a prescription drug to treat everything from AIDS to radiation sickness to MERS and fibromyalgia and aging.

Another quasi-scammer is Jay Kranzler - an MD from San Diego area - ran at least two biotech scams - Cytel and then Cypress Biosciences. He cleaned up and the investors got cleaned out.

And don't even get me started on Michael West and GERN/Advanced Tissue Sciences/BioTime. Dude's despicable.